Dividend Information About AbbVie: Everything You Need to Know Before Its Ex-Dividend Date on Oct 15, 2025
Generado por agente de IAAinvest Dividend Digest
sábado, 11 de octubre de 2025, 7:24 pm ET1 min de lectura
ABBV--
AbbVie (ABBV) has announced its upcoming cash dividend, offering shareholders $1.64000 per share. The dividend will be paid out on Nov 14, 2025, with an ex-dividend date set for Oct 15, 2025. Shareholders must own the stock by the close of trading on Oct 15, 2025, to be eligible for this payout. The company made the announcement on Sep 5, 2025, marking the formal declaration of the upcoming dividend. The most recent dividend was also $1.64000 per share, paid on Aug 15, 2025, and was also a cash dividend. The average of the last 10 dividend amounts stands at $0.99196 per share, meaning this time’s payout is significantly higher compared to the historical average. These details highlight AbbVie’s consistent dividend policy and its current generous payout to shareholders.
Over the past week, AbbVieABBV-- has attracted attention due to several key developments. Most recently, the company announced its intention to host a third-quarter 2025 earnings conference call, signaling its readiness to provide updated financial insights to the market. Analysts have noted a positive shift in sentiment, with price targets raised to $232.78, reflecting expectations of strong growth from recent strategic initiatives. As of late, AbbVie’s stock has demonstrated solid performance, with a 30-day share price return of nearly 10% and a year-to-date gain exceeding 28%, building momentum and reinforcing investor confidence. Additionally, the stock has been rated “Buy” by key market participants, with a 12-month target price of $232.85, indicating a slight upside from the current price of $230.50. These developments collectively point to a strengthening business outlook and favorable market conditions for AbbVie.
With these positive fundamentals and a generous dividend offering, AbbVie continues to attract both income-focused and growth-oriented investors. The ex-dividend date of Oct 15, 2025, marks the final opportunity for investors to purchase shares and receive the $1.64000 per share dividend. Investors who buy the stock after this date will not be eligible for the upcoming payout, underscoring the importance of timing for those seeking to benefit from AbbVie’s current dividend yield.
Over the past week, AbbVieABBV-- has attracted attention due to several key developments. Most recently, the company announced its intention to host a third-quarter 2025 earnings conference call, signaling its readiness to provide updated financial insights to the market. Analysts have noted a positive shift in sentiment, with price targets raised to $232.78, reflecting expectations of strong growth from recent strategic initiatives. As of late, AbbVie’s stock has demonstrated solid performance, with a 30-day share price return of nearly 10% and a year-to-date gain exceeding 28%, building momentum and reinforcing investor confidence. Additionally, the stock has been rated “Buy” by key market participants, with a 12-month target price of $232.85, indicating a slight upside from the current price of $230.50. These developments collectively point to a strengthening business outlook and favorable market conditions for AbbVie.
With these positive fundamentals and a generous dividend offering, AbbVie continues to attract both income-focused and growth-oriented investors. The ex-dividend date of Oct 15, 2025, marks the final opportunity for investors to purchase shares and receive the $1.64000 per share dividend. Investors who buy the stock after this date will not be eligible for the upcoming payout, underscoring the importance of timing for those seeking to benefit from AbbVie’s current dividend yield.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios